Aspirin

證據等級: L5

預測適應症: 0 個

Aspirin: Evaluation Report — Evidence Pack Incomplete, Re-generation Required

One-Sentence Summary

Aspirin (acetylsalicylic acid) is a well-established analgesic, antipyretic, and antiplatelet agent with decades of clinical use across multiple indications. However, this Evidence Pack contains no predicted new indications and carries two flagged data gaps at Blocking and High severity, meaning a complete drug repurposing evaluation cannot be performed at this time. UK regulatory records returned zero marketing authorisations, which is inconsistent with Aspirin’s known presence in the UK market and almost certainly reflects a data retrieval failure rather than true market absence.

Quick Overview

Item	Content
Original Indication	Not recorded in this Evidence Pack
Predicted New Indication	None — `predicted_indications` list is empty
TxGNN Prediction Score	Not available
Evidence Level	L5 — No predictions generated; cannot be assessed
UK Market Status	Not recorded (data shows “未上市” — likely a retrieval error)
Number of Marketing Authorisations	0 (likely a retrieval error — Aspirin holds multiple MHRA licences)
Recommended Decision	Hold

UK Market Information

No marketing authorisation records were returned for Aspirin in this Evidence Pack. This is inconsistent with the known UK market: aspirin-containing products hold numerous MHRA marketing authorisations covering indications including analgesia, antipyresis, and secondary prevention of cardiovascular events, and are listed throughout the BNF (sections 2.9 and 4.7.1).

A re-query against the MHRA Product Licence database is strongly recommended before proceeding.

Marketing Authorisation Number	Product Name	Dosage Form	Approved Indication
—	No records returned	—	Re-query required

Safety Considerations

No safety data is available in this Evidence Pack. Please refer to the current Aspirin Summary of Product Characteristics (SmPC) and the BNF for full safety information, including known contraindications (e.g., active peptic ulcer, known hypersensitivity, children under 16 with viral illness) and drug interactions (e.g., anticoagulants, NSAIDs, methotrexate).

Report any suspected adverse reactions via the Yellow Card Scheme (https://yellowcard.mhra.gov.uk/).

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is functionally incomplete — no predicted indications were generated by the TxGNN pipeline, the DrugBank ID field is null (blocking the prediction run), and two formal data gaps (DG001 at Blocking severity; DG002 at High severity) remain unresolved. No evaluation of repurposing potential is possible in this state.

To proceed, the following is needed:

Confirm DrugBank ID for Aspirin (expected: DB00945); the current pack returns null, which is likely the root cause of the empty prediction list
Re-run TxGNN prediction pipeline once the DrugBank ID is resolved
Resolve DG001 — retrieve SmPC warnings and contraindications from the MHRA website or eMC (https://www.medicines.org.uk/emc/)
Resolve DG002 — retrieve mechanism of action data via DrugBank API using DB00945
Re-query MHRA Product Licence database to populate UK marketing authorisation records
Re-generate this Evidence Pack (version v5 or later) once all inputs are confirmed and the pipeline completes successfully

This report is intended for research purposes only and does not constitute medical advice. All drug repurposing candidates require prospective clinical validation before any therapeutic application. Please refer to the current SmPC and BNF before prescribing.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.